Sulfation-dependent down-regulation of interferon-γ-induced major histocompatibility complex class I and II and intercellular adhesion molecule-1 expression on tubular and endothelial cells by glycosaminoglycans

Transplantation

Volumn 66, Issue 9, 1998, Pages 1244-1250

  Yard, Benito A ^a   Lorentz, Christian P ^a   Herr, Dieter ^b   Van Der Woude, Fokko J ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; GAMMA INTERFERON; GLYCOSAMINOGLYCAN; HEPARINOID; INTERCELLULAR ADHESION MOLECULE 1; LOW MOLECULAR WEIGHT HEPARIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PROTEOHEPARAN SULFATE; SODIUM CHLORATE;

ANTIGEN EXPRESSION; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GRAFT REJECTION; HUMAN; HUMAN CELL; INFLAMMATORY CELL; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; KIDNEY TUBULE EPITHELIUM; MAJOR HISTOCOMPATIBILITY COMPLEX; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; SULFATION;

EID: 0032533767     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199811150-00021     Document Type: Article

References (42)

1. Hall BM. Cells mediating allograft rejection. Transplantation 1991; 51: 1141.
2. Colvin RB, Cohen AR, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: reproducibility, sensitivity and clinical correlation. J Am Soc Nephrol 1997; 8:1930.
3. Miltenburg AMM, Meyer-Paape ME, Daha MR, et al. Donor-specific lysis of human kidney proximal tubular epithelial cells by renal allograft infiltrating lymphocytes. Transplantation 1989; 48: 296.
4. Van der Woude FJ, Daha MR, Miltenburg AMM, van Es LA. Renal allograft infiltrated lymphocytes and proximal tubular cells: further analysis of donor-specific lysis. Hum Immunol 1990; 28:186.
5. Yard BA, Kooymans-Coutinho M, Reterink T, et al. T cell lines isolated from rejecting renal allografts: analysis of outgrowth, donor- and tissue specificity and T cell receptor V beta usage. Kidney Int 1993; 43, suppl, 39: 133.
6. Moolenaar W, Bruijn JA, Schrama E, et al. T cell receptors and ICAM-1 expression in renal allografts during rejection. Transplant Int 1991; 4:140.
7. Mason DW. Effector mechanisms in allograft rejection. Annu Rev Immunol 1986; 4: 119.
8. Bishop GA, Hall BM. Expression of leucocyte and adhesion molecules in the human kidney. Kidney Int 1989; 36: 1078.
9. Pasternak MS. Cytotoxic T lymphocytes. Adv Intern Med 1988; 33: 17.
10. Yu CL, Haskard DO, Cavender D, Johnson A, Ziff M. Human gamma interferon increases the binding of T lymphocytes to endothelial cells. Clin Exp Immunol 1985; 62: 554.
11. Bishop GA, Hall BM, Suranyi MG, Horvath JS, Dugging DJ. Expression of HLA antigens on renal tubular cells in culture. I. Evidence that mixed lymphocyte culture supernatants and gamma interferon increase both class I and class II HLA antigens. Transplantation 1986; 42: 671.
12. Nagano H, Nadeau KC, Takada M, Kusaka M, Tilney NL. Sequential cellular and molecular kinetics in acutely rejecting allografts in rats. Transplantation 1997; 63: 1101.
13. Osorio RW, Ascher NL, Jaenisch R, Freise CE, Roberts JP, Stock PG. Major histocompatibility complex class I deficiency prolongs islet survival. Diabetes 1993; 42: 1520.
14. Markman JF, Bassin H, Desai NM, et al. Indefinite survival of MHC class I deficient murine pancreatic islet allografts. Transplantation 1992; 54: 1085.
15. Wight TN, Heinegard DK, Hascall VC. Proteoglycans, structure and function from cell biology of extracellular matrix. New York: Plenum Press, 1991.
16. Casu B. Structure and biological activity of heparin. Adv Carbohydr Chem Biochem 1985; 43: 51.
17. Wardle EN, Uldall P. The effects of heparin in patients with accelerated hypertension, progressive nephritis and renal allografts. Br Med J 1972; 4: 135.
18. Lider O, Baharav E, Mekroy YA, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989; 83: 752.
19. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilaqua MP. Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993; 82: 3253.
20. Ekre HPT, Fjellner B, Hagermark O. Inhibition of complement dependent experimental inflammation in human skin by different heparin fractions. Int J Immunopharmacol 1986; 8: 277.
21. Ekre HPT. Inhibition of human and guinea pig complement by heparin fractions differing in affinity for antithrombin II or in average molecular weight. Int J Immunopharmacol 1985; 7: 271.
22. Ekre HPT, Naparstek Y, Lider O, et al. Anti-inflammatory effects of heparin and its derivatives; inhibition of complement and of lymphocyte migration. Adv Exp Med Biol 1992; 313: 329.
23. Rapraeger AC, Krufka A, Olwin BB. Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 1991; 252: 1705.
24. Douglas M, Rix D, Dark J, Talbot D, Kirby J. Examination of the mechanism by which heparin antagonizes activation of a model endothelium by interferon-gamma (IFN-γ). Clin Exp Immunol 1997; 107: 578.
25. Detrisac CJ, Sens MA, Garvin AJ, Spicer SS, Sens DA. Tissue culture of human kidney epithelial cells of proximal tubule origin. Kidney Int 1984; 25: 383.
26. Jaffe EA, Nachmann RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745.
27. Nagasawa K, Inoue Y, Kamata T. Solvolytic desulfation of glycosaminoglycuronan sulfates with dimethyl sulfoxide containing water or methanol. Carbohydr Res 1977; 58: 47.
28. Naggi A, Torri G, Casu B, et al. Supersulfated heparin fragments, a new type of low molecular weight hepatin: physicochemical and phrmacological properties. Biochem Pharmacol 1987; 36: 1895.
29. Hurt-Camejo E, Rosengreen B, Camejo G, Sartipy P, Fager G, Bondjers G. Interferon-gamma binds to extracellular matrix chondroitin-sulphate, thus enhancing its cellular response. Arterioscler Thromb Vasc Biol 1995; 15: 1456.
30. Lortat-Jacob H, Grimaud HA. Interferon gamma binds to heparan sulphate by a cluster of amino acids located in the C-terminal part of the molecule. FEBS Lett 1991; 82:152.
31. Rix DA, Douglas D, Talbot JH, Dark JH, Kirby JA. Role of glycosaminoglycans (GAGs) in regulation of the immunogenicity in human vascular endothelial cells. Clin Exp Immunol 1996; 104: 60.
32. Lortat-Jacob H, Grimaud JA. Binding of interferon-gamma to heparan sulphate is restricted to the heparin-like domains and involves carboxylic- but not N-sulphated groups. Biochim Biophys Acta 1992; 1117: 126.
33. Keller KM, Brauer PR, Keller JM. Modulation of sulfate structure by growth of cells in the presence of chlorate. Biochemistry 1989; 28: 8100.
34. Takada M, Nadeau KC, Shaw GD, Marquette KA, Tilney NL. The cytokine-adhesion moleculae cascade in ischemia/reperfusion injury of the rat kidney: inhibition by a soluble P-selectin ligand. J Clin Invest 1997; 99: 2682.
35. Shoskes DA, Halloran PF. Delayed graft function in renal transplantation: etiology, management and long-term significance. J Urol 1996; 155: 1831.
36. Serrick C, La Franchesca S, Giad A, Shennib H. Cytokine interleukin-2, tumor necrosis factor-alpha, and interferon-gamma release after ischemia/reperfusion injury in a novel lung autograft in animal model. Am J Respir Crit Care Med 1995; 152: 277.
37. Halloran PF, Goes N, Urmson J, et al. MHC expression in organ transplants: lessons from the knock-out mice. Transplant Proc 1997; 29: 1041.
38. Lortat-Jacob H, Baltzer F, Grimaud JA. Heparin decreases the blood clearance of IFN-γ and increases its activity by limiting the processing of its carboxyl-terminal. J Biol Chem 1996; 271: 16139.
39. Stevens RB, Wang YL, Kaji H, et al. Administration of nonanticoagulant heparin inhibits the loss of glycosaminoglycans from xenogeneic cardiac grafts and prolongs graft survival. Transplant Proc 1993; 25: 382.
40. Akyürek ML, Larsson E, Funa K, Wanders A, Kaaijser M, Fellström BC. Experimental transplant arteriosclerosis: inhibition by angiopeptin and low molecular weight heparin derivatives. Transplant Proc 1995; 27: 3555.
41. Plissonnier D, Amichot G, Lecagneux J Duriez M, Gentric D, Michel JB. Additive and synergistic effect of a low-molecular weight, heparin-like molecule and low doses of cyclosporin in preventing arterial graft rejection in rats. Arterioscler Thrombosis 1993; 13: 112.
42. Handeland GF, Abildgaard U. Assay of unfractionated and LMW heparin with chromogenic substrates: twin methods with factor Xa and thrombin. Thrombosis Res 1984; 35: 627.